Research Article
Nephrotoxicity Evaluation on Cisplatin Combined with 5-HT3 Receptor Antagonists: A Retrospective Study
Table 1
Baseline characteristics of the 600 study patients.
| | Characteristic | All patients | Cisplatin + ondansetron | Cisplatin + tropisetron | Cisplatin + ramosetron | | () | () | () | () |
| | Sex | | | | | | Male | 375 (62.5%) | 108 (54%) | 114 (57%) | 153 (76.5%) | | Female | 225 (37.5%) | 92 (46%) | 86 (43%) | 47 (23.5%) | | PS | | | | | | 0-1 | 554 (92.3%) | 185 (92.5%) | 189 (94.5%) | 180 (90%) | | 2 | 46 (7.7%) | 15 (7.5%) | 11 (5.5%) | 20 (10%) | | Weight (kg) | | | | | | mean | 63 | 62 | 65 | 61 | | range | 42–90 | 45–86 | 42–90 | 45–78 | | ≥70 | 535 (89.2%) | 174 (87%) | 185 (92.5%) | 176 (88.0%) | | <70 | 65 (10.8%) | 26 (13%) | 15 (7.5%) | 24 (12%) | Baseline Ccr
(mL/min) | | | | | | mean | 99.5 | 97.1 | 104.7 | 96.6 | | range | 45.3–205.8 | 51.3–158.6 | 45.3–205.8 | 54.9–196.0 | Ccr during treatment
(mL/min) | | | | | | mean | 86.3 | 92.4 | 93.8 | 72.8 | | range | 42.2–181.6 | 48.9–147.4 | 42.2–181.6 | 43.5–121.1 | | Cisplatin dose (mg) | | | | | | mean | 76.7 | 74 | 76 | 80 | | range | 60–120 | 60–120 | 60–110 | 60–100 | | Age (years) | | | | | | mean | 56 | 54 | 56 | 58 | | range | 18–81 | 36–75 | 28–81 | 18–75 | | ≥70 | 55 (9.2%) | 16 (8.0%) | 21 (10.5%) | 18 (9.0%) | | <70 | 545 (90.8%) | 184 (92%) | 179 (89.5%) | 182 (91%) | | Tumor type | | | | | | Esophageal | 87 (14.5%) | 10 (5.0%) | 15 (7.5%) | 62 (31%) | | Lung | 164 (27.3%) | 36 (18%) | 41 (20.5%) | 87 (43.5%) | | Gastric | 31 (5.2%) | 4 (2.0%) | 7 (3.5%) | 20 (10.0%) | | Cervical | 87 (14.5%) | 32 (16.0%) | 47 (23.5%) | 8 (4.0%) | | Endometrial | 27 (4.5%) | 20 (10.0%) | 4 (2.0%) | 3 (1.5%) | | Bronchial | 173 (28.8%) | 99 (49.5%) | 47 (23.5%) | 27 (13.5%) | | Others | 31 (5.2%) | 12 (6.0%) | 15 (7.5%) | 4 (2.0%) |
|
|
